Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

120.55 +2.11 (+1.78%)
Streaming Delayed Price Updated: 10:59 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
66 67 Next >
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
 
Via Benzinga
Large Cap Biopharmaceuticals Performance
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant improvements in cholestasis markers and pruritus. 
Via Benzinga
The P3 App: Empowering and Elevating Underprivileged Youth from Socioeconomically Disadvantaged Areas Through Innovative Mentorship
CHICAGO - May 18, 2024 - PRLog -- The Pulse of Perseverance alongside Gilead is proud to announce the launch of the P3 mobile app, a pioneering platform unveiled at our signature benefit event on May... 
Via PRLog
Market Whales and Their Recent Bets on GILD Options
 
Via Benzinga
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
 
Via Benzinga
Why NASDAQ:GILD qualifies as a good dividend investing stock.
Why GILEAD SCIENCES INC (NASDAQ:GILD) is a Top Pick for Dividend Investors. 
Via Chartmill
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns. 
Via InvestorPlace
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
From Gilead Sciences, Inc.
Via Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,300 Today
 
Via Benzinga
Gilead Sciences Unusual Options Activity For May 06
 
Via Benzinga
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
If you want your shot at significant upside, speculate on these stocks near 52-week lows that can prove the critics wrong. 
Via InvestorPlace
How Is The Market Feeling About Gilead Sciences?
 
Via Benzinga
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May. 
Via InvestorPlace
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Gilead Sciences Unusual Options Activity
 
Via Benzinga
Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss?
Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury. 
Via Investor's Business Daily
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
3 Dividend Stocks to Buy at a 52-Week Low in April
Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors. 
Via InvestorPlace
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
GILD earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Gilead Sciences Announces First Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NASDAQ:META) are being compounded by weaker-than-expected economic growth... 
Via Benzinga
Topics Economy
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.